
I van O
@onco_uroloog
Not using X anymore, after so many years since it’s no longer compatible with my values
ID: 800864275
03-09-2012 17:39:15
5,5K Tweet
1,1K Followers
1,1K Following


Sub-stratification of current NCCN high-risk prostate cancer may lead to better patient prognostication and counseling: rdcu.be/c4iqN Ahmed Mansour, Harshit Garg MCh MBBS MD, Furkan Dursun, Michael Liss,Dharam Kaushik,Rob Svatek Luca Cindolo


Prostate Cancer and Prostatic Diseases selected the most significant research papers on #ProstateCancer 👉 doi.org/10.1038/s41391… 🎉 Proud of our team Peltier Alexandre Thierry Roumeguere Yassir Belahsen 👉 doi.org/10.1038/s41391…

Metastatic prostate cancer patients benefit from patient involvement in decisions: rdcu.be/c4WMF Frank Schumacher Alicia Morgans, MD, MPH Tanya Dorff Cosimo De Nunzio I van O Andrew Armstrong

Glad to see that our modest single arm phase 2 NEAR trial of neoadjuvant APA was cited as the top stories published in Prostate Cancer and Prostatic Diseases in 2022! Kudos to the team for pushing this through 💪🏻 JanssenUS Suneel Mundle Kae Jack Tay Ravindran Kanesvaran Joe Yeong nature.com/articles/s4139…


Our UCSF prostate cancer cohort shows that men who develop a detectable serum PSA >6 months after surgery may still have excellent long-term outcomes: rb.gy/vxhyls @JSzymaniakMD Cosimo De Nunzio

Podcasts are a useful way to provide public education about #prostatecancer genetics: rdcu.be/c5KqA #podcast #pcsm Stacy Loeb, MD

Find out more on the Schelin Catheter for analgesia during Rezum: rdcu.be/c5YCV Luca Cindolo Boston Scientific Urology @BSCEMEA_UroPH #anagesia #Practice




Jonathan O'Brien & Declan Murphy deliver one of highest quality videos of #EAU23 with slick, professional production values. This is how all videos should be put together! If only rest of our community had skills of this group. Key message: RP is safe/feasible after #Lutectomy



Meet the Editorial Board: Luca Cindolo expert in BPH/LUTS and minimally invasive surgery. Thanks for the great support to the journal! Luca Cindolo #editorial #pcsm #team #urosome


In our new paper in Clinical Cancer Research: plasma ctDNA% in pts with mCRPC after 4 wks of abi/enza tx inform on subsequent duration of response (outperforming clinical variables). Can on-treatment ctDNA changes guide an early treatment switch or intensification? aacrjournals.org/clincancerres/…


This study was led by two top Dutch trainees: Drs. Sofie Tolmeijer & Emmy Boerrigter, as part of a long-standing collaboration with Profs Niven Mehra and Nielka van Erp (RadboudUMC) and ably supported by several members of my lab Vancouver Prostate Centre 👏


